Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Astrazeneca (AZNCF) Equity Average (2016 - 2025)

Historic Equity Average for Astrazeneca (AZNCF) over the last 16 years, with Q4 2025 value amounting to $47.3 billion.

  • Astrazeneca's Equity Average rose 1593.37% to $47.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $47.3 billion, marking a year-over-year increase of 1593.37%. This contributed to the annual value of $44.8 billion for FY2025, which is 1193.57% up from last year.
  • Per Astrazeneca's latest filing, its Equity Average stood at $47.3 billion for Q4 2025, which was up 1593.37% from $45.4 billion recorded in Q3 2025.
  • Astrazeneca's Equity Average's 5-year high stood at $47.3 billion during Q4 2025, with a 5-year trough of $13.2 billion in Q1 2021.
  • Moreover, its 5-year median value for Equity Average was $38.0 billion (2022), whereas its average is $36.2 billion.
  • Its Equity Average has fluctuated over the past 5 years, first skyrocketed by 20921.16% in 2021, then tumbled by 882.21% in 2022.
  • Over the past 5 years, Astrazeneca's Equity Average (Quarter) stood at $39.6 billion in 2021, then dropped by 8.82% to $36.1 billion in 2022, then rose by 5.78% to $38.2 billion in 2023, then grew by 6.92% to $40.8 billion in 2024, then rose by 15.93% to $47.3 billion in 2025.
  • Its Equity Average stands at $47.3 billion for Q4 2025, versus $45.4 billion for Q3 2025 and $43.0 billion for Q2 2025.